SAB Biotherapeutics
Stock Forecast, Prediction & Price Target
SAB Biotherapeutics Financial Estimates
SAB Biotherapeutics Revenue Estimates
SAB Biotherapeutics EBITDA Estimates
SAB Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $60.87M N/A | $23.90M -60.73% | $2.23M -90.63% | Avg: $921.01K Low: $906.23K High: $930.86K avg. -58.86% | Avg: $215.45M Low: $211.99M High: $217.75M avg. 23292.77% | Avg: $1.45M Low: $1.42M High: $1.46M avg. -99.32% | Avg: $1.30M Low: $1.28M High: $1.31M avg. -10.28% |
Net Income
% change YoY
| $-17.44M N/A | $-18.74M -7.43% | $-42.19M -125.14% | Avg: $-50.74M Low: $-28.49M High: $-5.90M avg. -20.25% | Avg: $-57.00M Low: $-30.69M High: $-6.01M avg. -12.34% | Avg: $-6.12M Low: $-6.21M High: $-6.00M avg. 89.24% | Avg: $-5.74M Low: $-5.82M High: $-5.62M avg. 6.30% |
EBITDA
% change YoY
| $-11.71M N/A | $-27.15M -131.91% | $-38.07M -40.19% | Avg: $-517.56K Low: $-523.09K High: $-509.25K avg. 98.64% | Avg: $-121.07M Low: $-122.36M High: $-119.12M avg. -23292.81% | Avg: $-814.92K Low: $-823.64K High: $-801.85K avg. 99.32% | Avg: $-731.07K Low: $-738.88K High: $-719.34K avg. 10.28% |
EPS
% change YoY
| -$6.38 N/A | -$4.31 32.44% | -$7.64 -77.26% | Avg: -$3.26 Low: -$5.16 High: -$1.07 avg. 57.28% | Avg: -$3.33 Low: -$5.56 High: -$1.09 avg. -1.88% | Avg: -$1.11 Low: -$1.13 High: -$1.09 avg. 66.61% | Avg: -$1.04 Low: -$1.05 High: -$1.02 avg. 6.30% |
Operating Expenses
% change YoY
| $13.39M N/A | $28.91M 115.91% | $40.31M 39.41% | Avg: $2.06M Low: $2.03M High: $2.09M avg. -94.86% | Avg: $484.13M Low: $476.36M High: $489.30M avg. 23292.78% | Avg: $3.25M Low: $3.20M High: $3.29M avg. -99.32% | Avg: $2.92M Low: $2.87M High: $2.95M avg. -10.28% |
FAQ
What is SAB Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 15.73% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -28.49M, average is -50.74M and high is -5.90M.
What is SAB Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 5781.07% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $906.23K, average is $921.01K and high is $930.86K.
What is SAB Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 32.07% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$5.16, average is -$3.26 and high is $-1.07.
What is the best performing analyst?
In the last twelve months analysts have been covering SAB Biotherapeutics stock. The most successful analyst is Edward White.